華盛昌(002980.SZ):新冠抗原自測產品獲得俄羅斯註冊
格隆匯11月28日丨華盛昌(002980.SZ)公佈,公司新型冠狀病毒抗原檢測試劑盒於近日取得俄羅斯聯邦衞生保健監督局頒發的醫療器械註冊證書。產品名稱:COVID-19 Antigen Rapid Test [中文譯名:新型冠狀病毒抗原檢測試劑盒];預期用途:該產品採用一種檢測新型冠狀病毒(SARS-CoV-2)病毒核衣殼(N)蛋白的免疫層析法,用於體外定性檢測人前鼻拭子標本中的新型冠狀病毒抗原;證書有效期限:2025年1月1日。
公司上述新型冠狀病毒抗原檢測試劑盒可用於居家自測,無需檢測設備,具有易於操作、快速出結果的特點,方便個人及家庭進行新冠病毒的快速檢測。該產品獲得俄羅斯聯邦註冊,表明了該產品符合俄羅斯聯邦相關要求,可在俄羅斯聯邦進行銷售。該產品獲得上述註冊,將進一步增強公司的綜合競爭力,對公司產品在相應市場的推廣和銷售起到積極推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.